A Systematic Evaluation of Cost-Saving Dosing Regimens for Therapeutic Antibodies and Antibody-Drug Conjugates for the Treatment of Lung Cancer
ConclusionsDosing regimens based on weight bands and the use of complete vials to reduce drug wastage result in less expenses while maintaining equivalent exposure. The level of evidence of our proposal is the same as accepted by regulatory authorities for the approval of alternative dosing regimens of other monoclonal antibodies in oncology. The proposed alternative dosing regimens can, therefore, be directly implemented in clinical practice. (Source: Targeted Oncology)
Source: Targeted Oncology - April 21, 2023 Category: Cancer & Oncology Source Type: research
Improved Efficacy of First-Line Imatinib in Advanced Gastrointestinal Stromal Tumors (GIST): The Dutch GIST Registry Data
ConclusionThis study provides an update on outcomes of imatinib in the treatment of advanced GIST patients and demonstrates improved clinical outcomes since the first randomized studies of imatinib 2 decades ago. Furthermore, these results represent outcomes in real-world clinical practice and can serve as a reference when evaluating effectiveness of imatinib in patients with advanced GIST. (Source: Targeted Oncology)
Source: Targeted Oncology - April 20, 2023 Category: Cancer & Oncology Source Type: research
Place in Therapy of Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: A Targeted Literature Review
AbstractCyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) are the preferred regimen for patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2 −) advanced or metastatic breast cancer. However, the optimal treatment sequencing for CDK4/6i with other available therapeutic options is unclear. We conducted a targeted literature review to identify the current evidence on CDK4/6i treatment patterns in patients with breast cancer. The search wa s initially conducted in October 2021 and subsequently updated in October 2022. Biomedical databases and gray literature were searched...
Source: Targeted Oncology - April 19, 2023 Category: Cancer & Oncology Source Type: research
A Phase I Clinical Trial Evaluating the Safety and Dosing of Relugolix with Novel Hormonal Therapy for the Treatment of Advanced Prostate Cancer
ConclusionsCombination therapy of relugolix and abiraterone or apalutamide was associated with a favorable safety and tolerability profile consistent with the known profiles of the individual medications. Castration levels of testosterone were maintained after transitioning to relugolix from other ADTs.Clinical Trial RegistrationClinicalTrials.gov identifier: NCT04666129 (Source: Targeted Oncology)
Source: Targeted Oncology - April 15, 2023 Category: Cancer & Oncology Source Type: research
A Phase I, First-in-Human Study of PRL3-zumab in Advanced, Refractory Solid Tumors and Hematological Malignancies
ConclusionsPRL3-zumab, a first-in-class humanized antibody, was safe and tolerable in solid tumors and hematological malignancies. (Source: Targeted Oncology)
Source: Targeted Oncology - April 15, 2023 Category: Cancer & Oncology Source Type: research
A Multicenter, Phase II Trial of Schedule Modification for Nab-Paclitaxel in Combination with Ramucirumab for Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer: The B-RAX Trial (JACCRO GC-09)
ConclusionsThe primary endpoint for PFS was statistically not met, but modification of nab-PTX plus RAM to a bi-weekly schedule might be a feasible treatment option as second-line treatment for advanced GC/GJC patients, especially elderly patients, with severe AEs during the first cycle. (Source: Targeted Oncology)
Source: Targeted Oncology - April 15, 2023 Category: Cancer & Oncology Source Type: research
Genomic Landscape of Primary Resistance to Osimertinib Among Hispanic Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC): Results of an Observational Longitudinal Cohort Study
ConclusionEGFR-independent alterations are common among patients with primary resistance to osimertinib and significantly impact PFS and OS. Our results suggest that among Hispanic patients, other variables associated with intrinsic resistance include the number of commutations, high levelsAXL mRNA, and low levels ofBIM mRNA, T790M de novo,EGFR p.L858R presence, and a high tumoral mutational burden. (Source: Targeted Oncology)
Source: Targeted Oncology - April 5, 2023 Category: Cancer & Oncology Source Type: research
Comparison of Outcomes Between Therapeutic Combinations Based on Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitor Monotherapy for First-Line Therapy of Patients with Advanced Renal Cell Carcinoma Outside of Clinical Trials: A Real-World Retrospective Multi-Institutional Study
ConclusionsThe present study, using real-world data, provides evidence indicating the therapeutic benefit of ICI-based combination therapy over TKIs for advanced renal cell carcinoma was more statistically significant in the trial-ineligible population than in the trial-eligible population. (Source: Targeted Oncology)
Source: Targeted Oncology - March 21, 2023 Category: Cancer & Oncology Source Type: research
Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis?
ConclusionAdherence to the IMbrave150 trial inclusion criteria favorably impacts the prognosis of patients receiving atezolizumab plus bevacizumab. Among patients who did not meet the IMbrave150 inclusion criteria, those with ALBI grade 1 could benefit from the treatment. (Source: Targeted Oncology)
Source: Targeted Oncology - March 15, 2023 Category: Cancer & Oncology Source Type: research
Long-Term Real-World Outcomes and Safety of Vemurafenib and Vemurafenib + Cobimetinib Therapy in Patients with BRAF-Mutated Melanoma
ConclusionsWe confirmed significant improvement in the mOS and mPFS of unresectable and/or metastaticBRAF mutated-melanoma patients treated outside clinical trials with V + C as compared with V, with no major increase in toxicity for the combination. (Source: Targeted Oncology)
Source: Targeted Oncology - March 11, 2023 Category: Cancer & Oncology Source Type: research
Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunichLMU Molecular Tumor Board
ConclusionsThis single-center experience emphasizes the challenges of targeted treatment in pancreatic cancer. Very few patients ultimately received the recommended therapies, highlighting the need for more and better targeted treatment options in pancreatic cancer, early comprehensive genomic profiling to allow sufficient time to put Molecular Tumor Board recommendations into practice, and close cooperation with clinical trial units to give patients access to otherwise not available targeted treatments. (Source: Targeted Oncology)
Source: Targeted Oncology - February 28, 2023 Category: Cancer & Oncology Source Type: research
Abemaciclib: A Review in Early Breast Cancer with a High Risk of Recurrence
AbstractAbemaciclib [Verzenio® (USA) or Verzenios® (EU)] is a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor approved in combination with adjuvant endocrine therapy for patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2 −), node-positive, early breast cancer with a high risk of recurrence. In a phase III trial, abemaciclib plus endocrine therapy reduced the risk of recurrence of breast cancer compared with endocrine therapy alone, including in patients who had previously received neoadjuvant chemotherapy, in pati ents with high- and low-scoring Ki-67 tumours, and ...
Source: Targeted Oncology - February 24, 2023 Category: Cancer & Oncology Source Type: research
Analysis of Anti-Angiogenesis-Related Adverse Events Associated with Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitors (VEGFR-TKIs) in Patients with Metastatic Renal Cell Carcinoma
ConclusionsMore than half and more than one-third of patients with renal cell carcinoma receiving VEGFR-TKIs experienced any and severe anti-angiogenesis-related adverse events, respectively. The relative dose intensity of VEGFR-TKI treatment was associated with anti-angiogenesis-related adverse events. (Source: Targeted Oncology)
Source: Targeted Oncology - February 24, 2023 Category: Cancer & Oncology Source Type: research
FT-6876, a Potent and Selective Inhibitor of CBP/p300, is Active in Preclinical Models of Androgen Receptor-Positive Breast Cancer
ConclusionOur findings demonstrate FT-6876 as a promising new CBP/p300 bromodomain inhibitor, with efficacy in preclinical models of AR+ breast cancer. (Source: Targeted Oncology)
Source: Targeted Oncology - February 24, 2023 Category: Cancer & Oncology Source Type: research
Afatinib in Untreated Stage IIIB/IV Lung Adenocarcinoma with Major Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations (G719X/L861Q/S768I): A Multicenter Observational Study in Taiwan
ConclusionsFirst-line afatinib therapy is effective and safe for advanced lung adenocarcinoma harboring uncommon EGFR mutations. The G719X mutation was an independent factor associated with a favorable outcome. Poor performance (ECOG PS ≥ 2), brain metastasis, and liver metastasis were predictive factors of shorter PFS with first-line afatinib therapy.Graphical Abstract (Source: Targeted Oncology)
Source: Targeted Oncology - February 20, 2023 Category: Cancer & Oncology Source Type: research
